Posts by: Marisa Wexler, MS

Marisa Wexler, MS

Marisa holds an MS in Cellular and Molecular Pathology from the University of Pittsburgh, where she studied novel genetic drivers of ovarian cancer. She specializes in cancer biology, immunology, and genetics. Marisa began working with BioNews in 2018, and has written about science and health for SelfHacked and the Genetics Society of America. She also writes/composes musicals and coaches the University of Pittsburgh fencing club.

May 31, 2020June 1, 2020

TLY012 Receives FDA Orphan Drug Status for Systemic Scleroderma

News

The U.S. Food and Drug Administration has granted orphan drug designation to Theraly Fibrosis’ TLY012 for the treatment of systemic scleroderma. This designation is given to medications with the ... Read more

May 18, 2020May 18, 2020

Experts Issue Guidance for Care of Scleroderma Patients During COVID-19

News

With the World Scleroderma Foundation (WSF)’s support, experts worldwide answered questions in the form of recommendations for scleroderma patients amid the COVID-19 outbreak, including the importance of maintaining current medications ... Read more

March 13, 2020March 13, 2020

Heart, Kidney Imaging Could Detect Fibrosis in Scleroderma, Study Finds

News

Heart and kidney imaging may help detect fibrosis, or scarring, in asymptomatic people with scleroderma, and could be useful in routine evaluations for people with the disease, a study suggests. ... Read more

March 9, 2020March 9, 2020

Tracleer Seen to Ease Skin Symptoms in Small Scleroderma Study

News

One year of treatment with Tracleer (bosentan) significantly reduces the severity of patient-reported skin symptoms in people with scleroderma, a new study suggests. Yet, these benefits are diminished among ... Read more

February 24, 2020February 24, 2020

Autoantibodies Better Predictors of Scleroderma Prognosis Than Disease Overlap, Study Finds

News

The types of autoantibodies a person has are a better predictor of scleroderma prognosis than whether the person has other connective tissue diseases, a study reports. The study, “Clinical characteristics ... Read more

January 27, 2020January 28, 2020

Younger Age at Scleroderma Onset, Being Male Linked to Digital Ulcers, Study Reports

News

Scleroderma patients who develop digital ulcers are more likely to be younger at disease onset, male, and have the diffuse type of the disease, a study has found. Digital ... Read more

January 15, 2020January 15, 2020

FDA Paves Way for Phase 2 Testing of EHP-101 for Scleroderma

News

The U.S. Food and Drug Administration (FDA) has cleared an application from Emerald Health Pharmaceuticals that paves the way to begin a Phase 2 clinical trial testing EHP-101 in people ... Read more

December 13, 2019December 13, 2019

Similar Symptoms Found in Scleroderma Patients in the U.S., Regardless of Their Immunosuppressant Use, Study Finds

News

About a third of people diagnosed with scleroderma in the U.S. were prescribed immunosuppressive therapies in the first year after their diagnosis, but their symptoms were found to be ... Read more

November 4, 2019November 4, 2019

Letairis Fails To Lower PH, But Improves Cardiac Function, Blood Flow in Scleroderma, Phase 2 Trial Shows

News

Treatment with Letairis (ambrisentan) failed to significantly reduce pulmonary blood pressure at rest and during exercise compared with a placebo in people with scleroderma and mild pulmonary hypertension (PH), a ... Read more

October 7, 2019October 7, 2019

Phase 2 Study of Bermekimab in Treating Scleroderma Enrolls 1st Patient

News

The first person has been enrolled in a clinical trial evaluating the investigational therapy bermekimab in adults with scleroderma, XBiotech, the developer of bermekimab, announced. Although the cause of scleroderma ... Read more

Pin It on Pinterest